Skip to main content

Table 1 Patient characteristics and SOX11 staining

From: Expanded clinical and experimental use of SOX11 - using a monoclonal antibody

Method Entity N (M/F) Age range (mean) SOX11-C1 staining (P/T)1
IHC-P, TMA2 MCL 15 (12/3) 44-82 (68) 15/15, (15/16)5
IHC-P, TMA FL 15 (7/8) 49-92 (66) 0/15
IHC-P, TMA CLL 14 (10/4) 41-82 (70) 0/14
IHC-P, WTS3 HCL 7 (7/0) 37-64 (51) 0/7
IHC-P, WTS BL 4 (2/2) 3-12 (8) 2/4
IHC-P, WTS T-lymphoblastic 4 (3/1) 13-70 (53) 0/4
IHC-P, WTS B-lymphoblastic 2 (0/2) 14-69 (42) 0/2
IHC-P, TMA Tonsil 13 (5/8) 5-48 (24) 0/13
IHC-P, WTS Bone marrow 5 (3/2) 30-74 (49) 0/5
Flow cytometry MCL 54 (2/3) 50-80 (69) 5/5
Flow cytometry FL 2 (0/2) 70-76 0/2
Flow cytometry PBMC n.a n.a 0/2
Flow cytometry Tonsil n.a <7 0/2
  1. 1Number of positive (P) cases/Total number (T) of tested cases in IHC or flow cytometry.
  2. 2Tissue micro array (TMA).
  3. 3Whole tissue section (WTS).
  4. 4 Includes two cases of peripheral blood.
  5. 5A single previously negative case was selected, tested (WTS) and confirmed to be negative in IHC.